Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells

Targeting TRAIL in the treatment of cancer: new developments

(2015) Bora Lim et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

(2015) Jean Jacques Grob et al.   LANCET ONCOLOGY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing

(2015) Y-T Oh et al.   ONCOGENE

Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling

(2015) You-Take Oh et al.   Oncotarget

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors

(2014) M Holderfield et al.   BRITISH JOURNAL OF CANCER

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

(2014) Douglas B. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

B-Raf and the inhibitors: from bench to bedside

(2013) Tiangui Huang et al.   Journal of Hematology & Oncology

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

(2013) Geoffrey T. Gibney et al.   Nature Reviews Clinical Oncology

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

(2013) Alastair J. King et al.   PLoS One

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

(2013) Tara R. Rheault et al.   ACS Medicinal Chemistry Letters

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression

(2011) L. Dhandapani et al.   CANCER RESEARCH

Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling

(2011) You-Take Oh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting RAF: trials and tribulations

(2011) Julian Downward   NATURE MEDICINE

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Recent Advances in the Research and Development of B-Raf Inhibitors

(2010) Hui-Fang Li et al.   CURRENT MEDICINAL CHEMISTRY

Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation

(2010) S. Mocellin   CURRENT MEDICINAL CHEMISTRY

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation

(2010) Annie Yang et al.   CURRENT OPINION IN CELL BIOLOGY

ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1

(2010) You-Take Oh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

New insights into apoptosis signaling by Apo2L/TRAIL

(2010) F Gonzalvez et al.   ONCOGENE

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

(2009) Peter Hersey et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY